{
    "nct_id": "NCT01994382",
    "official_title": "A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\nPhase 1 Inclusion\n\n• Participant at least 18 years of age with histologically confirmed CLL/SLL or B-cell non-Hodgkin lymphoma (diffuse large B-cell lymphoma \\[DLBCL\\], FL, mantle cell lymphoma \\[MCL\\], marginal zone lymphoma \\[MZL\\], lymphoplasmacytic lymphoma).\n\nPhase 2a Inclusion\n\n* Histological evidence: FL Grade 1-3A, with relapsed or refractory disease; aggressive NHL (aNHL), defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, peripheral T-cell lymphoma (PTCL), or cutaneous T-cell lymphoma (CTCL) (with mycosis fungoides \\[MF\\]/Sézary Syndrome \\[SS\\]) with relapsed or refractory disease\n* Received B-cell receptor (BCR) and/or BCL2 inhibitors and were intolerant or had relapsed/refractory disease afterwards\n* Prior treatment for lymphoid malignancy for progressive /refractory disease\n* ≥1 prior regimen (minimum 2 cycles) with antibody conjugate/cytotoxic chemotherapy.\n* Measurable disease defined as: ≥1 lesion that measures ≥1.5 centimeter (cm) single dimension via computed tomography (CT), CT/positive-emission tomography (PET) with nodal or mass lesions; quantifiable circulating tumor cells; and for CTCL: Modified Severity Weighted Assessment Tool (mSWAT) \\>0\n* Ability to provide diagnostic reports\n\nGeneral Inclusion\n\n* Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1\n* Hematologic absolute neutrophil count (ANC) \\>1000/microliter (uL) and platelet \\>75,000/uL\n* Creatinine levels as specified by Investigator\n* Bilirubin \\<2.0 mg/deciliter \\[dL\\] (if Gilberts then \\<2.5 mg/dL) and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \\<2.5\\*ULN\n\nExclusion Criteria:\n\n* Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL from follicular NHL are eligible)\n* Prior transplant with stem cell infusion within 90 days of Day 1 or active graft-versus-host treatment within 8 weeks of Day 1\n* Prior therapy with Spleen Tyrosine Kinase (SYK) inhibitors\n* Chronic treatment with strong CYP3A4 inhibitor/inducer\n* Known lymphomatous involvement of the central nervous system (CNS)\n* Persistent, unresolved National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0 ≥Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy).\n* Prior monoclonal antibody (including alemtuzumab), radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any test agent within 3 weeks of Day 1\n* For CTCL: (total skin electron beam therapy \\[TSEBT\\]) within 12 weeks, or initiation of topical steroid, nitrogen mustard, or topical retinoid within 2 weeks. Stable topical regimen for ≥4 weeks prior to Day 1 allowed.\n* Known carrier or infection for human immunodeficiency virus (HIV)/hepatitis B or C. If hepatitis C virus (HCV) antibody (ab)+, must be polymerase chain reaction (PCR)- to be eligible. If hepatitis B virus (HBV) ab+, must be hepatitis B surface antigen (HBsAg)- or undetectable HBV deoxyribonucleic acid (DNA) to be eligible.\n* Active infection requiring systemic treatment,\n* Significant gastrointestinal (GI) disease, previous major gastric/bowel surgery, difficulty swallowing, or malabsorption syndrome\n* Major surgery within 4 weeks\n* Previous malignancies within 2 years unless relapse risk is small (\\<5%).\n* Current use of systemic steroids \\>20 mg QD prednisone (or equivalent)\n* Breastfeeding or pregnant (intention to become) females or participation in other clinical trials\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "Phase 1 Inclusion\n\n• Participant at least 18 years of age with histologically confirmed CLL/SLL or B-cell non-Hodgkin lymphoma (diffuse large B-cell lymphoma [DLBCL], FL, mantle cell lymphoma [MCL], marginal zone lymphoma [MZL], lymphoplasmacytic lymphoma).\n\nPhase 2a Inclusion\n\n* Histological evidence: FL Grade 1-3A, with relapsed or refractory disease; aggressive NHL (aNHL), defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, peripheral T-cell lymphoma (PTCL), or cutaneous T-cell lymphoma (CTCL) (with mycosis fungoides [MF]/Sézary Syndrome [SS]) with relapsed or refractory disease\n* Received B-cell receptor (BCR) and/or BCL2 inhibitors and were intolerant or had relapsed/refractory disease afterwards\n* Prior treatment for lymphoid malignancy for progressive /refractory disease\n* ≥1 prior regimen (minimum 2 cycles) with antibody conjugate/cytotoxic chemotherapy.\n* Measurable disease defined as: ≥1 lesion that measures ≥1.5 centimeter (cm) single dimension via computed tomography (CT), CT/positive-emission tomography (PET) with nodal or mass lesions; quantifiable circulating tumor cells; and for CTCL: Modified Severity Weighted Assessment Tool (mSWAT) >0\n* Ability to provide diagnostic reports\n\nGeneral Inclusion\n\n* Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1\n* Hematologic absolute neutrophil count (ANC) >1000/microliter (uL) and platelet >75,000/uL\n* Creatinine levels as specified by Investigator\n* Bilirubin <2.0 mg/deciliter [dL] (if Gilberts then <2.5 mg/dL) and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) <2.5*ULN",
        "exclusion": "* Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL from follicular NHL are eligible)\n* Prior transplant with stem cell infusion within 90 days of Day 1 or active graft-versus-host treatment within 8 weeks of Day 1\n* Prior therapy with Spleen Tyrosine Kinase (SYK) inhibitors\n* Chronic treatment with strong CYP3A4 inhibitor/inducer\n* Known lymphomatous involvement of the central nervous system (CNS)\n* Persistent, unresolved National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0 ≥Grade 2, previous drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy).\n* Prior monoclonal antibody (including alemtuzumab), radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any test agent within 3 weeks of Day 1\n* For CTCL: (total skin electron beam therapy [TSEBT]) within 12 weeks, or initiation of topical steroid, nitrogen mustard, or topical retinoid within 2 weeks. Stable topical regimen for ≥4 weeks prior to Day 1 allowed.\n* Known carrier or infection for human immunodeficiency virus (HIV)/hepatitis B or C. If hepatitis C virus (HCV) antibody (ab)+, must be polymerase chain reaction (PCR)- to be eligible. If hepatitis B virus (HBV) ab+, must be hepatitis B surface antigen (HBsAg)- or undetectable HBV deoxyribonucleic acid (DNA) to be eligible.\n* Active infection requiring systemic treatment,\n* Significant gastrointestinal (GI) disease, previous major gastric/bowel surgery, difficulty swallowing, or malabsorption syndrome\n* Major surgery within 4 weeks\n* Previous malignancies within 2 years unless relapse risk is small (<5%).\n* Current use of systemic steroids >20 mg QD prednisone (or equivalent)\n* Breastfeeding or pregnant (intention to become) females or participation in other clinical trials"
    }
}